Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
IN8BIO, INC. (INAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/18/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/18/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2023 SC 13G Ho William Tai-Wei reports a 11.5% stake in IN8bio, Inc.
08/11/2023 SC 13G Transcend Partners Opportunity Fund LLC reports a 13% stake in IN8bio, Inc.
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology Annual Meeting showing 100% of treated patients have exceeded historical median progression-free survival • INB-400 on track to initiate enrollment in glioblastoma multiforme in the second half of 2023. The Phase 2 trial will initially enroll newly diagnosed GBM patients in the autologous setting. The primary endpoint of the study is overall survival ; secondary endpoints include tolerability, progression-free survival , overall response rate and time to progression • Promising preclinical data in ovarian cancer announced at the American Society of Gene & Cell Therapy Annual Mee..."
07/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-100 data showing long-term complete remissions and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose for the ongoing expansion with clinical updates expected in late 2023. • Progress across preclinical programs, including data demonstrating that gamma-delta T cells have the ability to target other solid tumors, including ovarian cancer, expanding the scope of their potential application beyond brain tumors, as well as encouraging preclinical data in the new INB-330 CAR-T program targeting acute myeloid leukemia . • Obtained FDA orphan drug designation for INB-400 and INB-410, wh..."
05/01/2023 8-K Quarterly results
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/24/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
02/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue"
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals"
12/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma"
12/06/2022 8-K/A Quarterly results
Docs: "8-K/A",
"IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress"
11/22/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/13/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/19/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/12/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
08/12/2022 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy